Purple biotech reaches recommended phase 2 dose for nt219

Rehovot, israel, feb. 01, 2024 (globe newswire) -- purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has determined 100mg/kg is the recommended phase 2 dose (rp2d) for nt219 in combination with cetuximab in the treatment of head and neck cancer based on its phase 1/2 dose escalation study (nct04474470). nt219 is a first-in-class small molecule dual inhibitor of irs1/2 and stat3.
PPBT Ratings Summary
PPBT Quant Ranking